Fruth Investment Management maintained its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,580 shares of the medical research company’s stock at the end of the second quarter. Fruth Investment Management’s holdings in Amgen were worth $272,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in Amgen during the fourth quarter valued at approximately $275,209,000. RB Capital Management LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $764,000. Pinnacle Financial Partners Inc. boosted its stake in shares of Amgen by 9.1% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 31,896 shares of the medical research company’s stock valued at $4,664,000 after buying an additional 2,663 shares in the last quarter. ARS Investment Partners LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $278,000. Finally, Barings LLC boosted its stake in shares of Amgen by 3.5% in the fourth quarter. Barings LLC now owns 66,566 shares of the medical research company’s stock valued at $9,733,000 after buying an additional 2,230 shares in the last quarter. 79.12% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.81 on Friday. The firm’s 50 day moving average is $174.19 and its 200 day moving average is $167.96. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The firm has a market capitalization of $122.45 billion, a PE ratio of 15.28 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.84 EPS. Analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be paid a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.74%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
ILLEGAL ACTIVITY WARNING: This report was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/18/fruth-investment-management-has-272000-stake-in-amgen-inc-nasdaqamgn-updated-updated.html.
A number of research firms recently weighed in on AMGN. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus increased their price objective on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. UBS AG set a $180.00 target price on shares of Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus price target of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.
About Amgen
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
